Navigation Links
IVI announces the prequalification of innovative cholera vaccine by the World Health Organization
Date:11/11/2011

Institute of Hygiene and Epidemiology and production experts at Shantha, IVI enabled technology transfer from Vabiotech, a vaccine manufacturer in Vietnam, to Shantha for the production of cholera vaccine. IVI also established and transferred tests to ensure the vaccine was of the highest quality and enabled improvements in production to keep manufacturing costs as low as possible.

"This important milestone validates Vabiotech's efforts and technical capability in developing and promoting the manufacture of an affordable cholera vaccine for the world's poorest people," said Dr. Nguyen Thu Van, Director General of Vabiotech. "We are eager to see this vaccine rapidly deployed, especially in endemic areas, amid recent outbreaks of cholera in Africa, Asia and the Caribbean."

A Phase III clinical trial performed by IVI and colleagues at India's National Institute of Cholera and Enteric Diseases was launched at a field site in Kolkata to evaluate the vaccine in people from ages one year and up. The results showed the vaccine to be safe and protective against cholera for three years in all age groups. Licensed in India in 2009, Shanchol was the first vaccine to be developed and licensed from the pipeline of vaccines being developed with support from the Bill & Melinda Gates Foundation

"Prequalification of the Shanchol vaccine by WHO represents a validation of Shantha's quality processes and the safety and efficacy of the vaccine," said Dr. Harish Iyer, Chief Executive Officer of Shantha Biotechnics. "This approval also reinforces our commitment to work with partners to provide vaccines against infectious diseases affecting developing countries."

The prequalification by WHO sets the stage for IVI's next planned phase of the vaccine, which is introducing Shanchol in countries where cholera remains a major public health problem, such as countries in Africa and South Asia where the disease is endemic. Recently IVI estimated that nearly
'/>"/>

Contact: Tae Kyung Byun
tkbyun@ivi.int
82-119-773-6071
International Vaccine Institute
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. AMRI announces collaboration agreement with Lilly for in-sourced chemistry services
2. University of Michigan announces Eric J. Topol Professorship in Cardiovascular Medicine
3. Peter Thiel announces Breakout Labs to energize innovation
4. ESC announces review of Atrial Fibrillation Guidelines
5. The Waxman Foundation announces $25,000 grant in B-cell lymphoma research
6. INFORMS journal announces special issue on using logistics, analytics in humanitarian relief
7. ASTRO announces 2011 Fellows class
8. The New York Stem Cell Foundation announces new initiative for Parkinsons disease
9. AFAR announces the 2011 Hartford Scholars in Geriatric Medicine
10. AGA announces prestigious recognition award recipients
11. Sanofi Pasteur announces FDA approval of menactra meningococcal conjugate vaccine indication for infants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... (PRWEB) May 29, 2015 News: 2015-2016 ... , Company website: http://www.carsonenergy.com , In ... rapidly, due to the boom in US shale production ... in order to regain market share from US shale ... realized by putting more oil out into the marketplace, ...
(Date:5/29/2015)... Wimbledon Health Partners, the leading on-site ... and NCV testing, is proud to announce the ... EKG interpretation of athletes. , Sudden cardiac ... athletic activity. New findings presented in February have played ... cardiac safety in athletes. Physiologic adaptations in athletic individuals ...
(Date:5/29/2015)... Thursday, May 21st was the inaugural Red Nose ... of life came together to raise money for kids living ... campaign dedicated to raising money for children and young people ... laugh, the people at Hands-On Seminars decided to host their ... provided food, fun and laughter to their visitors, while raising ...
(Date:5/29/2015)... Belviq for weight loss , also ... medication. In 2012, the FDA approved Belviq specifically ... BMI >30. It is also approved for individuals ... weight-related health condition such as high blood pressure, diabetes, ... for weight loss focuses on the brain’s appetite center. ...
(Date:5/28/2015)... External Counterpulsation (EECP/ECP) has been used extensively all ... There are a growing number of people with advanced ... angina and these patients are often times not amenable ... “No option” patients are a sizable cohort of population ... considered unacceptable for heart stent or bypass. The Heart ...
Breaking Medicine News(10 mins):Health News:Breaking News: Carson Energy Releases 2015-2016 Oil Forecast 2Health News:Wimbledon Health Partners Incorporates Updated ‘Seattle Criteria’ for EKG Interpretation of Athletes 2Health News:Wimbledon Health Partners Incorporates Updated ‘Seattle Criteria’ for EKG Interpretation of Athletes 3Health News:Groups, such as Hands-On Physical Therapy, Across the Country, Host Their Own Events and Make the Inaugural Red Nose Day a Huge Success 2Health News:Belviq for Weight Loss is Now Available to Qualified Diet Doc Patients Nationwide 2Health News:Belviq for Weight Loss is Now Available to Qualified Diet Doc Patients Nationwide 3Health News:External Counterpulsation (EECP/ECP) a New Heart Disease Therapy Helps People of Calgary with Unstable Angina 2
... HealthDay Reporter , MONDAY, July 25 (HealthDay News) ... in people with diabetes could also help predict their risk ... -- which measures levels of hemoglobin A1c (HbA1c) in blood ... blood sugar is controlled over several months. Diabetes is a ...
... immediate release - July 26 (Toronto) - People who ... to develop Parkinson,s disease than those who did not, ... and Mental Health (CAMH). The researchers examined almost ... admitted to hospital for methamphetamine or amphetamine-use disorders had ...
... [EMBARGOED FOR JULY 26, 2011] Antibiotic overuse and resistance ... decades. Following an outbreak of Clostridium difficile infections, which ... Quebec, Canada targeted physicians and pharmacists with an education ... study published in Clinical Infectious Diseases and ...
... July 25 (HealthDay News) -- Hospitalized patients who are able ... satisfied with their care, but one-fifth are not given the ... The authors of the new study compiled information on the ... three-year period, and had the patients rate their sense of ...
... July 25, 2011 UT Southwestern Medical Center ... prostate cancer by demonstrating that late-stage tumors are driven ... While testosterone is generally known to stimulate ... is resistant to standard hormonal therapy actually is driven ...
... 2011 Researchers from New England report in a new ... with an endoscopic ultrasound if the tumor marker is elevated, ... a high-risk population than by using the standard means of ... GIE: Gastrointestinal Endoscopy , the monthly peer-reviewed scientific journal of ...
Cached Medicine News:Health News:Blood Test May Better Predict Diabetics' Heart Risk: Study 2Health News:Blood Test May Better Predict Diabetics' Heart Risk: Study 3Health News:Increased risk of Parkinson's disease in methamphetamine users, CAMH study finds 2Health News:Simple guidelines decreased unnecessary antibiotic use in Quebec, Canada 2Health News:Spiritual Talks May Boost Patients' View of Hospital Care 2Health News:UT Southwestern scientists discover new pathway to potential therapies for advanced prostate cancer 2Health News:Study examines screening for pancreatic cancer in high-risk populations 2Health News:Study examines screening for pancreatic cancer in high-risk populations 3Health News:Study examines screening for pancreatic cancer in high-risk populations 4
(Date:5/29/2015)... and MENLO PARK, Calif. ... DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and ... and commercializing proven cancer therapies in new orphan ... American Association of Cancer Research (AACR) Advances ... potential for its lead product candidate VAL-083 ...
(Date:5/29/2015)... Pa. , May 29, 2015 ... focus of the Association for the Advancement of ... With support from AAWC,s corporate partners, ... Educational Portal on the AAWC website at ... a wound care pathway with links to various ...
(Date:5/28/2015)... May 28, 2015 ... the addition of Jain PharmaBiotech,s new report  ...  to their offering.       (Logo: ... gene silencing involves the use of double ... this material is processed into short 21-23 ...
Breaking Medicine Technology:DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 2DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 3DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 4DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 5The Association for the Advancement of Wound Care Educates the Public 2Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 2Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 3
The Hydroflex Arthroscopic Irrigation Pump is simple to transport, set-up and tear down. The pump is streamlined with a simple control panel an no transducers or electronics to control flow. It is co...
... The hands play an important part in ... impairments and rheumatic changes can cause severe ... of the finger-joint prostheses was to produce ... the natural function as nearly possible.,The cementless ...
The OsteoJect Bone Cement Delivery System now offers leading technology to physicians with the first-ever reusable driver. The OsteoJect allows precise delivery of bone cement under active fluoro whi...
This high technology cast plaster cutter saw is very easy and comfortable to use....
Medicine Products: